(AOF) – OSE Immunotherapeutics announced a collaboration agreement with GenDx (Eurobio Scientific Group, a key player in the field of in vitro diagnostics). This will involve developing and validating a companion diagnostic test (CDx) as part of the preparation for the pivotal confirmatory phase 3 clinical trial of Tedopi, a cancer vaccine candidate. Tedopi is a second-line treatment for non-small cell lung cancer (NSCLC). GenDx develops and markets molecular diagnostics.
The objective of this study will be to confirm the effectiveness and safety of Tedopi in second line treatment after failure of checkpoint inhibitors (CPI) in HLA-A02 positive patients with NSCLC, to support the product registration in the United States and Europe.